title: Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
abstract: Polymeric micelles incorporating cisplatin (CDDP) were prepared through the polymer-metal complex formation between CDDP and poly(ethylene glycol)-poly(glutamic acid) block copolymers, and their utility as a tumor-targeted drug delivery system was investigated. CDDP-incorporated micelles (CDDP/m) had a size of 28 nm with remarkably narrow distribution. CDDP/m were very stable in distilled water even in long-time storage, but exhibited a sustained drug release accompanied with the decay of the carrier itself in physiological saline. These micelles showed remarkably prolonged blood circulation and effectively accumulated in solid tumors (Lewis lung carcinoma cells) according to the passive targeting manner (20-fold higher than free CDDP). Reduced accumulation of the micelles in normal organs provided high selectivity to the tumor. In vivo antitumor activity assay demonstrated that both free CDDP and the CDDP/m had significant antitumor activity in C 26-bearing mice compared with nontreatment (P < 0.05 for free CDDP; P < 0.01 for CDDP/m), but complete tumor regression was observed only for the treatment with CDDP/m. Four of 10 mice treated with CDDP/m (4 mg/kg; five times administration at 2-day intervals) showed complete tumor regression with no significant body weight loss, whereas free CDDP treatment at the same drug dose and regime resulted in tumor survivals and approximately 20% of body weight loss. These data suggest that CDDP/m could be a promising formulation of CDDP for the targeted therapy of solid tumors.
authors.affiliation: Department of Materials Science and Engineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Nishiyama
authors.forename: Souichiro
authors.initials: S
authors.lastname: Okazaki
authors.forename: Horacio
authors.initials: H
authors.lastname: Cabral
authors.forename: Masaki
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Yukio
authors.initials: Y
authors.lastname: Kato
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: Kazuto
authors.initials: K
authors.lastname: Nishio
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Matsumura
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kataoka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D002945:Cisplatin / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D020128:Inhibitory Concentration 50; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008823:Micelles; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D008823:Micelles; D002945:Cisplatin